Radiation-Free Bone Health Assessment Market Global Report 2026

The radiation-free bone health assessment market size has grown strongly in recent years. It will grow from $0.16 billion in 2025 to $0.17 billion in 2026 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to rising prevalence of osteoporosis, increasing awareness of preventive bone health screening, growing aging population, expanding utilization of non invasive diagnostic technologies, increasing focus on early detection of bone disorders.

The radiation-free bone health assessment market size is expected to see strong growth in the next few years. It will grow to $0.22 billion in 2030 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to growing adoption of portable bone assessment systems, increasing demand for radiation free diagnostic solutions, expanding public health screening initiatives, rising investment in preventive healthcare programs, increasing utilization of bone health monitoring services. Major trends in the forecast period include growing adoption of radiation free bone density screening, increasing use of portable bone health assessment devices, rising demand for frequent osteoporosis monitoring, expansion of community based bone health screening programs, growing preference for non invasive bone quality assessment.

The rising prevalence of osteoporosis and osteopenia is anticipated to drive the growth of the radiation-free bone health assessment market in the forecast period. Rising prevalence of osteoporosis and osteopenia refers to the growing number of individuals experiencing decreased bone mineral density, ranging from early-stage bone loss (osteopenia) to advanced bone weakening (osteoporosis), which increases the likelihood of fractures. The growing prevalence of osteoporosis and osteopenia is attributed to factors such as an aging population, an increasing postmenopausal population, inactive lifestyles, nutritional deficiencies, and the rising impact of chronic diseases that negatively affect bone health. With the increasing number of individuals vulnerable to fractures and bone-related complications, the demand for early diagnosis, regular bone density monitoring, and preventive healthcare interventions is also increasing, supporting the adoption of radiation-free bone health assessment technologies. For instance, in May 2024, according to the Bone Health And Osteoporosis Foundation (BHOF), a US-based nonprofit organization, around 10 million Americans were affected by osteoporosis, while another 44 million Americans had low bone density (osteopenia), increasing their risk of fractures. Therefore, the rising prevalence of osteoporosis and osteopenia is supporting the growth of the radiation-free bone health assessment market.

Key companies operating in the radiation-free bone health assessment market are focusing on expanding access to point-of-care osteoporosis screening through strategic partnerships and the implementation of radiation-free ultrasound technologies. Point-of-care osteoporosis screening enables rapid and non-invasive bone health evaluations in community and primary care settings, supporting early osteoporosis risk identification and timely preventive interventions. For example, in May 2026, Bone Index Finland Oy, a Finland-based medical technology company specializing in radiation-free bone density assessment solutions, partnered with Boots, a UK-based pharmacy-led healthcare and retail company, to launch a pilot Bone Density Scan Service using Bindex ultrasound technology at selected Boots pharmacies. The initiative aimed to improve access to early osteoporosis risk assessment through radiation-free, point-of-care screening in community healthcare settings. The pilot program was designed to integrate bone health screening into routine pharmacy services, enabling individuals to undergo a quick assessment without requiring a hospital visit. The collaboration sought to support earlier identification of individuals at risk of low bone mineral density, allowing timely referral for further clinical evaluation when appropriate. By expanding access to convenient community-based screening, the initiative aimed to increase public awareness of osteoporosis and encourage proactive bone health management.

In November 2024, Echolight S.p.A., an Italy-based medical technology company focused on radiation-free bone densitometry solutions, entered into a partnership with Siemens Healthineers. Through this collaboration, Siemens Healthineers broadened the availability of Echolight’s REMS-based bone densitometry systems in the US market, supporting the growing adoption of radiation-free technologies for bone health evaluation. Siemens Healthineers is a Germany-based medical technology company.

Major companies operating in the radiation-free bone health assessment market report are Echolight S.p.A., Esaote S.p.A., Furuno Electric Co. Ltd., OsteoSys Co. Ltd., BeamMed Ltd., Bone Index Finland Oy, CHISON Medical, SIUI (Shantou Institute of Ultrasonic Instruments Co. Ltd.), Alpinion Medical Systems Co. Ltd., Trivitron Healthcare, Vinno Technology Co. Ltd., Bone Health Screening Ltd, Precision Bone Imaging LLC, CyberLogic Inc., CompuMed Inc., Medonica Co. Ltd., POROUS GmbH.

Western Europe was the dominant region in the radiation-free bone health assessment market in 2025. North America is expected to be the rapidly growing region in the forecast period. The regions covered in the radiation-free bone health assessment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the radiation-free bone health assessment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 3-5 business days.